Redeye is encouraged to learn that the first healthy volunteer has been dosed in the company’s phase...
Redeye is positive about CLS’ first mobile service provider agreement with AVANT Concierge Urology i...
Redeye returns with a view on Tesofensine following the positive opinion of the drug as an obesity t...
Raute reports Q1 results on Apr 28. Large projects solidify outlook, while the new strategy hints at...
Clients still overstocked, but demand is holding up 3% q-o-q order booking decline '23e-'25e EBIT do...
Redeye thinks last night’s design win for access control could be towards Toyota, and that the proba...
Q1'23e should be solid... .. but few strategic updates likely after CMD in March Therefore, the repo...
Redeye comments on the results from the phase I/IIa trial of EVX-02 with 10 patients in adjuvant mel...
Redeye is encouraged by the first report from Annexin’s imaging study (n=16), which indicates site-s...
FY net profit guidance lifted 9-11% to DKK 210-240m (190-220m) Strong NII and asset quality offset h...
Redeye comments on today’s press release, underlining the company’s critical financial situation.
Sales +7% vs. ABGSCe, EBIT -14% vs. ABGSCe Organic growth of -13%, better than ABGSCe -24% We expect...
Redeye provides a research update following Hoylu’s Q1 2023 report.
Q1 report due on Wednesday, 3 May We expect the earnings trend to turn positive in Q1e 16-12x '23e-'...
Cantargia yesterday published important results in pancreatic cancer at the AARC annual meeting.
Both we and company-compiled consensus expect Netcompany to have continued solid revenue growth (12-...
Another bad debt provision likely to hurt Q1e, easing in Q2e We cut '23e sales by 8% and '24-'25e by...
OrderYOYO announced on Monday, April 17th, the company’s performance during Q1-23.
Redeye will likely increase its forecasts and Fair Value Range of Hanza in an Update following the f...
Analysguiden inleder bevakning av ventilationsbolaget Systemair med en riktkurs på 85 kronor.
